Notice: This company has been marked as potentially delisted and may not be actively trading. Oncobiologics (ONS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends ONS vs. TECX, PROK, AURA, GLUE, RGNX, TRML, TSHA, ATYR, PRME, and ALLOShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Tectonic Therapeutic (TECX), ProKidney (PROK), Aura Biosciences (AURA), Monte Rosa Therapeutics (GLUE), REGENXBIO (RGNX), Tourmaline Bio (TRML), Taysha Gene Therapies (TSHA), Atyr PHARMA (ATYR), Prime Medicine (PRME), and Allogene Therapeutics (ALLO). These companies are all part of the "medical" sector. Oncobiologics vs. Tectonic Therapeutic ProKidney Aura Biosciences Monte Rosa Therapeutics REGENXBIO Tourmaline Bio Taysha Gene Therapies Atyr PHARMA Prime Medicine Allogene Therapeutics Oncobiologics (NASDAQ:ONS) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations. Does the media refer more to ONS or TECX? In the previous week, Tectonic Therapeutic had 2 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 0 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.00 equaled Tectonic Therapeutic'saverage media sentiment score. Company Overall Sentiment Oncobiologics Neutral Tectonic Therapeutic Neutral Does the MarketBeat Community believe in ONS or TECX? Oncobiologics received 166 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. However, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 63.74% of users gave Oncobiologics an outperform vote. CompanyUnderperformOutperformOncobiologicsOutperform Votes17463.74% Underperform Votes9936.26% Tectonic TherapeuticOutperform Votes8100.00% Underperform VotesNo Votes Which has better earnings and valuation, ONS or TECX? Tectonic Therapeutic has lower revenue, but higher earnings than Oncobiologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologics$3.81M29.56-$38.84MN/AN/ATectonic TherapeuticN/AN/A$12.16M-$5.89-5.02 Which has more risk & volatility, ONS or TECX? Oncobiologics has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.62, indicating that its share price is 162% more volatile than the S&P 500. Do insiders & institutionals believe in ONS or TECX? 7.2% of Oncobiologics shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 11.5% of Oncobiologics shares are held by insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is ONS or TECX more profitable? Tectonic Therapeutic has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%. Oncobiologics' return on equity of 0.00% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets Oncobiologics-464.47% N/A -93.28% Tectonic Therapeutic N/A -35.53%-31.97% Do analysts prefer ONS or TECX? Tectonic Therapeutic has a consensus price target of $80.50, indicating a potential upside of 172.51%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Oncobiologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryTectonic Therapeutic beats Oncobiologics on 11 of the 15 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONS vs. The Competition Export to ExcelMetricOncobiologicsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.63M$3.11B$5.84B$9.14BDividend YieldN/A1.55%4.75%3.86%P/E RatioN/A30.1126.7719.18Price / Sales29.56329.47435.4570.78Price / CashN/A168.8738.0134.83Price / Book-1.153.687.644.62Net Income-$38.84M-$71.72M$3.19B$246.06M Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONSOncobiologicsN/A$1.56-4.9%N/A+278.0%$112.63M$3.81M0.00N/AHigh Trading VolumeTECXTectonic Therapeutic2.3146 of 5 stars$31.87-8.3%$80.50+152.6%N/A$470.08MN/A-5.41120Gap UpPROKProKidney1.3402 of 5 stars$1.55-2.5%$4.50+190.3%-1.3%$452.07MN/A-2.823Gap UpAURAAura Biosciences3.2194 of 5 stars$7.73-0.4%$23.00+197.5%-14.7%$386.11MN/A-4.4750GLUEMonte Rosa Therapeutics2.6664 of 5 stars$6.11-5.3%$14.00+129.1%+13.1%$375.40MN/A-3.3490Positive NewsRGNXREGENXBIO3.8995 of 5 stars$7.33-7.1%$33.45+356.4%-60.5%$363.13M$90.24M-1.46370Analyst RevisionTRMLTourmaline Bio1.7474 of 5 stars$12.88-7.5%$54.00+319.3%-66.2%$330.24MN/A-4.5744High Trading VolumeTSHATaysha Gene Therapies2.3535 of 5 stars$1.60-14.4%$6.63+314.1%-36.1%$327.91M$9.92M2.54180ATYRAtyr PHARMA2.8187 of 5 stars$3.71-1.6%$19.25+418.9%N/A$311.42M$350,000.00-3.9553Analyst ForecastAnalyst RevisionNews CoverageGap UpPRMEPrime Medicine2.5281 of 5 stars$2.28-5.8%$13.13+475.7%-65.1%$299.05MN/A-1.11234News CoverageALLOAllogene Therapeutics2.8363 of 5 stars$1.40-5.4%$9.73+595.2%-51.1%$293.54M$43,000.00-0.90310 Related Companies and Tools Related Companies TECX Alternatives PROK Alternatives AURA Alternatives GLUE Alternatives RGNX Alternatives TRML Alternatives TSHA Alternatives ATYR Alternatives PRME Alternatives ALLO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredThis quote from Elon says it all… (AI Breakthrough)MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
